Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 1/2009

01-12-2009 | Supplement Article

Chronic hepatitis B in Asian women of childbearing age

Author: Nancy Leung

Published in: Hepatology International | Special Issue 1/2009

Login to get access

Abstract

Hepatitis B virus (HBV) infection is a serious clinical problem affecting approximately 2 billion people worldwide. An estimated 350 million live with chronic hepatitis B (CHB) infection and are at an increased risk for serious liver sequelae and death from acute or chronic consequences of CHB infection. Individuals with CHB have a 20–30% risk of early death from complications, including liver cirrhosis and hepatocellular carcinoma. In the Asia-Pacific region, half of the CHB burden results from vertical or mother-to-child transmission, with early childhood horizontal transmission accounting for the remaining half. Screening and vaccination are key factors in the successful prevention and control of HBV infection. Over the last 20 years, the implementation of screening programs and universal HBV vaccination for all individuals born in endemic areas have reduced the prevalence of HBV infection and HBV-related liver diseases among individuals younger than 30 years. Women of childbearing age are key stakeholders in preventing HBV infection and, as such, play a critical role in reducing the vertical and horizontal transmission of HBV. Further efforts are needed to implement screening and educational programs for women of childbearing age, particularly those with CHB, to prevent the transmission of HBV to newborns, spouses, other household members, and sexual partners. In addition, healthcare workers need to learn how to avoid iatrogenic transmission in the healthcare setting. This article reviews these issues and highlights areas in which their engagement with public health efforts serves to improve quality of life and society as a whole.
Literature
1.
Zhao K. Epidemiology of hepatitis B in China. In Lam SK, Lai CL, Yeok EK, editors. Viral Hepatitis B Infection in the Western Pacific Region: Vaccine and Control. Singapore: World Scientific; 1984. 23–28
2.
Centers for Disease Control and Prevention. Progress in hepatitis B prevention through universal infant vaccination—China, 1997–2006. MMWR Morb Mortal Wkly Rep 2007;56:441–445
3.
Ebright JR, Altantsetseg T, Oyungerel R. Emerging infectious diseases in Mongolia. Emerg Infect Dis 2003;9:1509–1515PubMed
4.
Edstam JS, Dulmaa N, Nymadawa P, Rinchin A, Khulan J, Kimball AM. Comparison of hepatitis B vaccine coverage and effectiveness among urban and rural Mongolian 2-year-olds. Prev Med 2002;34:207–214PubMedCrossRef
5.
Hipgrave DB, Nguyen TV, Vu MH, Hoang TL, Do TD, Tran NT, et al. Hepatitis B infection in rural Vietnam and the implications for a national program of infant immunization. Am J Trop Med Hyg 2003;69:288–294PubMed
6.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97–107PubMedCrossRef
7.
Lin HH, Kao JH, Chang TC, Hsu HY, Chen DS. Secular trend of age-specific prevalence of hepatitis B surface and e antigenemia in pregnant women in Taiwan. J Med Virol 2003;69:466–470PubMedCrossRef
8.
Louisirirotchanakul S, Myint KS, Srimee B, Kanoksinsombat C, Khamboonruang C, Kunstadter P, et al. The prevalence of viral hepatitis among the Hmong people of northern Thailand. Southeast Asian J Trop Med Public Health 2002;33:837–844PubMed
9.
Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol 2000;15:1356–1361PubMedCrossRef
10.
Qu JB, Zhang ZW, Shimbo S, Watanabe T, Nakatsuka H, Matsuda-Inoguchi N, et al. Urban-rural comparison of HBV and HCV infection prevalence in eastern China. Biomed Environ Sci 2000;13:243–253PubMed
11.
Tran HT, Ushijima H, Quang VX, Phuong N, Li TC, Hayashi S, et al. Prevalence of hepatitis virus types B through E and genotypic distribution of HBV and HCV in Ho Chi Minh City. Vietnam Hepatol Res 2003;26:275–280CrossRef
12.
Wiwanitkit V, Suyaphan A. High prevalence of HBsAg seropositivity in Hilltribers in the Mae Jam district in northern Thailand. Med Gen Med 2002;4:26
13.
World Health Organization Regional Office for Western Pacific. REPORT on Working Group Meeting on Viral Hepatitis B. Manilla, Philippines: World Health Organization Regional Office for Western Pacific; July 2002. (WP)/ICP/EPI/5.2/001-A. Report Series No.: RS/2002/GE/05 (Japan)
14.
Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335–352PubMedCrossRef
15.
Lee AKY, Ip H, Wong VCW. Mechanisms of maternal-fetal transmission of hepatitis B virus. J Infect Dis 1978;138:668–671PubMed
16.
Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975;292:771–774PubMed
17.
Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Eng J Med 1997;336:1855–1859CrossRef
18.
19.
Chien YC, Jan CF, Kuo HS, Chen CJ. Nationwide hepatitis vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:126–135PubMedCrossRef
20.
Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007;132:1287–1294PubMedCrossRef
21.
Lau GKK, Carman C, Locarnini SA, Okuda K, Lu Z-M, William R, et al. Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. J Gastroenterol Hepatol 1999;14:3–12PubMedCrossRef
22.
23.
Fung J, Lai CL, But D, Wong D, Cheung TK, Yuen MF. Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management. Am J Gastroenterol 2008;103:1421–1426PubMedCrossRef
24.
Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984;13:385–391PubMedCrossRef
25.
Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies. J Med Virol 1993;71:360–366CrossRef
26.
Yuen MF, Yuan HJ, Hui CK, Wong DK, Wong WM, Chan AO, et al. A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003;52:416–419PubMedCrossRef
27.
Leung N, Yeung C, Chan R, et al. Features of chronic hepatitis B female patients of childbearing age in Hong Kong. Hepatol Int; 2009, in press
28.
29.
Carr BR, Parker CR Jr, Madden JD, MacDonald PC, Porter JC. Maternal plasma adenocorticotropin and cortisol relationships throughout human pregnancy. Am J Obstet Gynecol 1981;139:416–422PubMed
30.
Hidaka Y, Amino N, Iwatani Y, Kaneda T, Mitsuda N, Morimoto Y, et al. Changes in natural killer cell activity in normal pregnant and post-partum women increases in the first and second post-partum period and decrease in late pregnancy. J Reprod Immunol 1991;20:73–83PubMedCrossRef
31.
Lin HH, Chen PJ, Chen DS, Sung JL, Yang KH, Young YC, et al. Post-partum subsidence of hepatitis B viral replication in HBeAg positive carrier mothers. J Med Virol 1989;29:1–6PubMedCrossRef
32.
Söderström A, Norkrans G, Lindh M. Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003;35:814–819PubMedCrossRef
33.
Tan HH, Lui H-F, Chow W-C. Chronic hepatitis B virus (HBV) infection in pregnancy. Hepatol Int 2008;3:370–375CrossRef
34.
Liaw Y-F, Leung N, Kao J-H, Piratvisuth T, Gane E, Han K-H, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263–283PubMedCrossRef
35.
Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007;45:1056–1075PubMedCrossRef
36.
Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009;16:94–103PubMedCrossRef
37.
van Zonneveld M, van Nunen AB, Niesters HG, de Man RA, Schalm SW, Janssen HL. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294–297PubMedCrossRef
38.
van Nunen AB, de Man RA, Heijtink RA, Niesters HG, Schalm SW. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients. J Hepatol 2000;32:1040–1041PubMedCrossRef
39.
Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, et al. Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003;9:1501–1503PubMed
40.
Su G-G, Pan H-K, Zhao N-F, Fang SH, Yang DH, Zhou Y. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004;10:910–912PubMed
41.
Chotiyaputta W, Lok AS. Role of antiviral therapy in the prevention of perinatal transmission of hepatitis B virus infection (editorial). J Viral Hepat 2009;16:91–93PubMedCrossRef
42.
Chang MH. Decreasing incidence of hepatocellular carcinoma among children following universal hepatitis B immunization. Liver Int 2003;23:309–314PubMedCrossRef
43.
Hsu HY, Chang MH, Ni YH, Chen HL. Survey of hepatitis B surface variant infection in children 15 years after nation-wide vaccination program in Taiwan. Gut 2004;53:11499–11503CrossRef
44.
But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008;26:6587–6591PubMedCrossRef
45.
46.
Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006;11:1496–1502PubMedCrossRef
47.
Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65–73PubMedCrossRef
48.
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006;130:678–686PubMedCrossRef
49.
Nguyen VT, Law MG, Dore GJ. An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int 2008;28:525–531PubMed
50.
Koblin BA, Xu G, Lucy D, Robertson V, Bonner S, Hoover DR, et al. Hepatitis B infection and vaccination among high-risk non-injection drug-using women: baseline data from the UNITY study. Sex Transm Dis 2007;34:917–922PubMedCrossRef
51.
Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 2007;46:1034–1040PubMedCrossRef
52.
Taylor VM, Choe JH, Yasui Y, Li L, Burke N, Jackson JC. Hepatitis B awareness, testing, and knowledge among Vietnamese American men and omen. J Community Health 2005;30:477–490PubMedCrossRef
53.
Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57:1–20PubMed
54.
van der Eijk AA, de Man RA, Niesters HG, Schalm SW, Zaaijer HL. Hepatitis B virus (HBV) DNA levels and the management of HBV-infected health care workers. J Viral Hepat 2006;13:2–4PubMedCrossRef
Metadata
Title
Chronic hepatitis B in Asian women of childbearing age
Author
Nancy Leung
Publication date
01-12-2009
Publisher
Springer-Verlag
Published in
Hepatology International / Issue Special Issue 1/2009
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-009-9142-1

Other articles of this Special Issue 1/2009

Hepatology International 1/2009 Go to the issue

CME Post Test

CME post test

CME Information

CME information

SUPPLEMENT ARTICLE

On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48

Supplement Article

The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B

Supplement Article

Introduction
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits